A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 93,800 shares of TRDA stock, worth $1.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
93,800
Previous 44,600 110.31%
Holding current value
$1.65 Million
Previous $635,000 136.06%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$13.65 - $17.86 $671,580 - $878,712
49,200 Added 110.31%
93,800 $1.5 Million
Q2 2024

Aug 09, 2024

BUY
$11.85 - $16.45 $528,510 - $733,670
44,600 New
44,600 $635,000
Q2 2022

Aug 12, 2022

SELL
$5.49 - $12.94 $64,782 - $152,692
-11,800 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$7.99 - $16.93 $14,166 - $30,016
-1,773 Reduced 13.06%
11,800 $111,000
Q4 2021

Feb 11, 2022

BUY
$13.7 - $35.0 $185,950 - $475,055
13,573 New
13,573 $232,000

Others Institutions Holding TRDA

About Entrada Therapeutics, Inc.


  • Ticker TRDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,368,500
  • Market Cap $551M
  • Description
  • Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...
More about TRDA
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.